ACRES Commercial Realty Corp. ( ACR ) Nowojorska Giełda Papierów Wartościowych

Cena: 17.82 ( -0.11% )

Aktualizacja 06-20 15:53
Nowojorska Giełda Papierów Wartościowych
Branża: REIT - Mortgage

Notowania:


Informacje o spółce:
Sektor: Nieruchomości
Branża: REIT - Mortgage
Zatrudnienie: 4
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 88%
Ilość akcji: 8 455 130
Debiut giełdowy: 2006-02-07
WWW: https://www.acresreit.com
CEO: Mr. Mark Steven Fogel
Adres: 390 RXR Plaza
Siedziba: 11556 Uniondale
ISIN: US00489Q1022
Opis firmy:

ACRES Commercial Realty Corp., Trust Investment Investment Trust (REIT), koncentruje się na powstaniu, utrzymywaniu i zarządzaniu kredytami hipotecznymi nieruchomościami komercyjnymi oraz innymi inwestycjami zadłużenia związanym z nieruchomościami w nieruchomości w Stanach Zjednoczonych. Inwestuje w aktywa związane z nieruchomościami komercyjnymi, w tym zmiennoprzecinkową i stałą stawką pierwszą kredyty hipoteczne, pierwsze priorytetowe odsetki od pierwszych kredytów hipotecznych, odsetki podporządkowane pierwszych kredytów hipotecznych, zadłużenie mezzaniny, preferowane inwestycje kapitałowe, komercyjne kredyty papierów wartościowych oraz komercyjne inwestycje w nieruchomości i preferowane inwestycje w zakresie kapitału własnego. Firma kwalifikuje się jako fundusz inwestycyjny nieruchomości do celów federalnego podatku dochodowego. Zasadniczo nie podlegałby federalnego podatku dochodowego od osób prawnych w zakresie, w jakim rozdzieli 100% dochodu podlegającego opodatkowaniu REIT. Firma była wcześniej znana jako Exantas Capital Corp. i zmieniła nazwę na Acres Commercial Realty Corp. w lutym 2021 r. Akres Commercial Realty Corp. został zarejestrowany w 2005 r. I ma siedzibę w Uniondale w stanie Nowy Jork.

Wskaźniki finansowe
Kapitalizacja (USD) 131 764 466
Aktywa: 2 010 336 000
Cena: 17.82
Wskaźnik Altman Z-Score: -0.2
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: 63.6
Ilość akcji w obrocie: 88%
Średni wolumen: 35 451
Ilość akcji 7 394 190
Wskaźniki finansowe
Przychody TTM 150 676 000
Zobowiązania: 1 563 444 000
Przedział 52 tyg.: 12.7 - 23.81
Piotroski F-Score: 9
Silny (dobra jakość finansowa)
EPS: 0.3
P/E branży: 8.0
Beta: 2.051
Raport okresowy: 2025-07-29
WWW: https://www.acresreit.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Jaclyn Alyce Jesberger Chief Legal Officer, Senior Vice President & Secretary 413 985 1978
Mr. Eldron C. Blackwell Senior Vice President, Chief Financial Officer & Treasurer 315 362 1979
Mr. Mark Steven Fogel President, Chief Executive Officer & Director 0 1969
Mr. Steven Landgraber Senior Vice President of Corporate Finance & Investor Relations Officer 0 0
Mr. George Edward Carleton Executive Vice President of Resource America 0 1959
Ms. Linda M. Kilpatrick Vice President, Chief Accounting Officer & Controller 0 1973
Mr. Paul Andrew Hughson J.D. Executive Vice President of Commercial Real Estate Lending Business Division 0 1962
Mr. George E. Carlton Head of CMBS Investing 0 0
Mr. Kyle K. Brengel Vice President of Operations 0 1991
Mr. Jeffrey Dean Blomstrom Senior Vice President 0 1969
Wiadomości dla ACRES Commercial Realty Corp.
Tytuł Treść Źródło Aktualizacja Link
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass. globenewswire.com 2025-05-14 20:10:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. (ACR) Q1 2025 Earnings Call Transcript ACRES Commercial Realty Corp. (NYSE:ACR ) Q1 2025 Earnings Call May 1, 2025 10:00 AM ET Company Participants Kyle Brengel - Vice President, Operations Mark Fogel - President and Chief Executive Officer Eldron Blackwell - Chief Financial Officer Andrew Fentress - Chairman Conference Call Participants Matthew Erdner - Jones Trading Chris Muller - Citizens Capital Markets Operator Good day, ladies and gentlemen and welcome to the First Quarter 2025 ACRES Commercial Realty Corp. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. seekingalpha.com 2025-05-01 22:36:20 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. Reauthorizes an Additional $10 Million Share Repurchase Program UNIONDALE, N.Y. , April 30, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $10 million of the outstanding shares of both its common and preferred stock. prnewswire.com 2025-04-30 20:17:00 Czytaj oryginał (ang.)
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FIRST QUARTER 2025 UNIONDALE, N.Y. , April 30, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended March 31, 2025. prnewswire.com 2025-04-30 20:10:00 Czytaj oryginał (ang.)
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically globenewswire.com 2025-04-25 12:00:00 Czytaj oryginał (ang.)
Earn Double-Digit Returns With ACRES Commercial Realty Preferreds I compare ACR's preferred stocks, ACR.PR.C and ACR.PR.D, highlighting their dividend yields and potential returns, with a preference for dividend-focused investments. ACR.PR.C, a fixed-to-floating rate preferred stock, has provided a 48.1% total gain since my investment in October 2022. ACR.PR.D, a fixed-rate preferred stock, is expected to outperform ACR.PR.C in total return as the Federal Reserve lowers interest rates. seekingalpha.com 2025-04-21 18:05:35 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. to Report Results for First Quarter 2025 UNIONDALE, N.Y. , April 16, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the first quarter 2025, on Wednesday, April 30, 2025, after the market closes. prnewswire.com 2025-04-16 20:15:00 Czytaj oryginał (ang.)
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 WATERTOWN, Mass. globenewswire.com 2025-03-19 10:00:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock UNIONDALE, N.Y. , March 18, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock. prnewswire.com 2025-03-18 18:15:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. Announces Redemption of CRE Securitizations and Closing of a $940 Million Managed Facility Backed by Commercial Mortgage Loans UNIONDALE, N.Y. , March 17, 2025 /PRNewswire/ -- ACRES Commercial Realty (NYSE: ACR) (the "Company") announced that it repurchased the assets in ACRES Commercial Realty 2021-FL1 and ACRES Commercial Realty 2021-FL2 in their entirety and brought the existing JP Morgan warehouse facility balance to zero. prnewswire.com 2025-03-17 18:15:00 Czytaj oryginał (ang.)
ACRES Commercial Realty: Are The Commons Still A Buy? ACRES Commercial Realty Corp. is up substantially over the last 1-year as the mREIT moves to close its discount to book value. ACR's book value grew by 95 cents sequentially to $28.87 per share, with the commons currently trading hands at a 27% discount to book value. The floating rate Series C preferreds are a play for income, currently paying out a 10.4% yield on cost but trading 22 cents above their liquidation value per share. seekingalpha.com 2025-03-10 12:10:56 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. (ACR) Q4 2024 Earnings Call Transcript Start Time: 10:00 January 1, 0000 10:18 AM ET ACRES Commercial Realty Corp. (NYSE:ACR ) Q4 2024 Earnings Conference Call March 06, 2025, 10:00 AM ET Company Participants Mark Fogel - President and CEO Eldron Blackwell - CFO Andrew Fentress - Chairman Kyle Brengel - VP, Operations Conference Call Participants Matthew Erdner - Jones Trading Chris Muller - Citizens Bank Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2024 ACRES Commercial Realty Corp. Earnings Conference Call. Currently, all participants are in a listen-only mode. seekingalpha.com 2025-03-06 14:17:05 Czytaj oryginał (ang.)
ACRES Commercial (ACR) Q4 Earnings Surpass Estimates ACRES Commercial (ACR) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.55 per share a year ago. zacks.com 2025-03-05 21:50:23 Czytaj oryginał (ang.)
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FOURTH QUARTER 2024 AND YEAR ENDED DECEMBER 31, 2024 UNIONDALE, N.Y. , March 5, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter and year ended December 31, 2024. prnewswire.com 2025-03-05 18:15:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. to Report Results for Fourth Quarter 2024 UNIONDALE, N.Y. , Feb. 19, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the fourth quarter 2024, on Wednesday, March 5, 2025, after the market closes. prnewswire.com 2025-02-19 18:15:00 Czytaj oryginał (ang.)
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses Rosnilimab was safe and well tolerated with similar adverse event rates vs. globenewswire.com 2025-02-12 09:30:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program UNIONDALE, N.Y. , Dec. 19, 2024 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $5 million of the outstanding shares of both its common and preferred stock. prnewswire.com 2024-12-19 18:16:00 Czytaj oryginał (ang.)
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock UNIONDALE, N.Y. , Dec. 19, 2024 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock. prnewswire.com 2024-12-19 18:15:00 Czytaj oryginał (ang.)
The Only 3 REITs You Need to Own In Your Lifetime Investing in real estate investment trusts (REITs) is an excellent option for long-term investors looking to create meaningful passive income streams in retirement. 247wallst.com 2024-12-10 12:15:19 Czytaj oryginał (ang.)
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis. businesswire.com 2024-11-18 19:53:00 Czytaj oryginał (ang.)